The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients

Clinics

Volumn 66, Issue 4, 2011, Pages 579-582

  Cevikoi, Alev ^a   Umay, Ebru ^b   Polat, Sevgi ^a   Ecerkale, Oznur ^a   Cakci, Aytul ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b Beyazit Training and Research Hospital   (Turkey)

Author keywords

Bisphosphonates; Medication adherence; Medication persistence; Osteoporosis; Treatment effectivenes

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; CHI SQUARE DISTRIBUTION; DEMOGRAPHY; EDUCATIONAL STATUS; HUMAN; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; STATISTICS;

CHI-SQUARE DISTRIBUTION; DEMOGRAPHY; DIPHOSPHONATES; EDUCATIONAL STATUS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS;

EID: 79958734043     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000400010     Document Type: Article

References (18)

1. Consensus development conference: prophylaxis and treatment of osteoporosis. Br Med J. 1987;295: 914-915, doi: 10.1136/bmj.295.6603.914.
2. Dawson-Hughes B Prevention. In:Prevention. Riggs BL,Melton LG (eds.). Osteoporosis: Etiology, Diagnosis, and Management. 2nd ed. Philadelphia: Lippincott-Raven; 1995. p. 335-350.
3. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7:390-406.
4. Fleisch H. Bisphosphonates in osteoporosis: an introduction. Osteoporosis Int. 1993;3:3-5, doi: 10.1007/BF01623000.
5. Bartl R. Biologic half-life of bisphosphonates. Dtsch Med Wochenschr. 2009;134:651-6542, doi: 10.1055/s-0029-1208102.
6. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
7. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592, doi: 10. 1210/jc.87.4.1586.
8. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-1460, doi: 10.1185/030079905X61875.
9. Curtis JR, Westfall AO, Allison JJ, Freman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int. 2006;17:1268-1274, doi: 10.1007/s00198-006-0136-8.
10. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928, doi: 10.1016/j.bone.2005.10.022.
11. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with medication therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645-1652, doi: 10.1007/s00198-006-0179-x.
12. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L et al. Treatment of Osteoporosis in Clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17:914-921.
13. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17:922-928, doi: 10.1007/s00198-006-0085-2.
14. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, et al. Cost-effectiveness of bone densitometry followed by treatment of steoporosis in older men. JAMA. 2007;298: 629-637, doi: 10.1001/jama. 298.6.629.
15. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36(2):399-419, doi: 10.1016/j.ecl.2007.03.008.
16. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007;25:302-309, doi: 10.1007/s00774-007-0768-6.
17. Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME. Adherence to alendronate in male veterans. Osteoporos Int. 2008;19:349-356, doi: 10.1007/s00198-007-0471-4.
18. Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, et al. Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2009;20: 463-472, doi: 10.1007/s00198-008- 0674-3.